TY - JOUR
T1 - In Search of Multimodal Neuroimaging Biomarkers of Cognitive Deficits in Schizophrenia
AU - Sui, Jing
AU - Pearlson, Godfrey D.
AU - Du, Yuhui
AU - Yu, Qingbao
AU - Jones, Thomas R.
AU - Chen, Jiayu
AU - Jiang, Tianzi
AU - Bustillo, Juan
AU - Calhoun, Vince D.
N1 - Funding Information:
This work was supported by the National Institutes of Health Grants R01MH084898 (to JB) and R01EB 006841 , R01EB 005846 , and 5P20RR021938 (to VDC); “100 Talents Plan” of Chinese Academy of Sciences, the State High-Tech Development Plan of China (863) (Grant Number 2015AA020513 ), and Chinese National Science Foundation Number 81471367 (to JS); and the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant Number SQ2015AA02030300 ) and National Key Basic Research and Development Plan of China (973) (Grant Number 2011CB707800 ) (to TJ).
Funding Information:
This work was supported by the National Institutes of Health Grants R01MH084898 (to JB) and R01EB 006841, R01EB 005846, and 5P20RR021938 (to VDC); "100 Talents Plan" of Chinese Academy of Sciences, the State High-Tech Development Plan of China (863) (Grant Number 2015AA020513), and Chinese National Science Foundation Number 81471367 (to JS); and the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant Number SQ2015AA02030300) and National Key Basic Research and Development Plan of China (973) (Grant Number 2011CB707800) (to TJ). The authors report no biomedical financial interests or potential conflicts of interest.
Publisher Copyright:
© 2015 Society of Biological Psychiatry.
PY - 2015
Y1 - 2015
N2 - Background The cognitive deficits of schizophrenia are largely resistant to current treatments and thus are a lifelong illness burden. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) provides a reliable and valid assessment of cognition across major cognitive domains; however, the multimodal brain alterations specifically associated with MCCB in schizophrenia have not been examined. Methods The interrelationships between MCCB and the abnormalities seen in three types of neuroimaging-derived maps - fractional amplitude of low-frequency fluctuations (fALFF) from resting-state functional magnetic resonance imaging (MRI), gray matter (GM) density from structural MRI, and fractional anisotropy from diffusion MRI - were investigated by using multiset canonical correlation analysis in data from 47 schizophrenia patients treated with antipsychotic medications and 50 age-matched healthy control subjects. Results One multimodal component (canonical variant 8) was identified as both group differentiating and significantly correlated with the MCCB composite. It demonstrated 1) increased cognitive performance associated with higher fALFF (intensity of regional spontaneous brain activity) and higher GM volumes in thalamus, striatum, hippocampus, and the mid-occipital region, with co-occurring fractional anisotropy changes in superior longitudinal fascicules, anterior thalamic radiation, and forceps major; 2) higher fALFF but lower GM volume in dorsolateral prefrontal cortex related to worse cognition in schizophrenia; and 3) distinct domains of MCCB might exhibit dissociable multimodal signatures, e.g., increased fALFF in inferior parietal lobule particularly correlated with decreased social cognition. Medication dose did not relate to these findings in schizophrenia. Conclusions Our results suggest linked functional and structural deficits in distributed cortico-striato-thalamic circuits may be closely related to MCCB-measured cognitive impairments in schizophrenia.
AB - Background The cognitive deficits of schizophrenia are largely resistant to current treatments and thus are a lifelong illness burden. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) provides a reliable and valid assessment of cognition across major cognitive domains; however, the multimodal brain alterations specifically associated with MCCB in schizophrenia have not been examined. Methods The interrelationships between MCCB and the abnormalities seen in three types of neuroimaging-derived maps - fractional amplitude of low-frequency fluctuations (fALFF) from resting-state functional magnetic resonance imaging (MRI), gray matter (GM) density from structural MRI, and fractional anisotropy from diffusion MRI - were investigated by using multiset canonical correlation analysis in data from 47 schizophrenia patients treated with antipsychotic medications and 50 age-matched healthy control subjects. Results One multimodal component (canonical variant 8) was identified as both group differentiating and significantly correlated with the MCCB composite. It demonstrated 1) increased cognitive performance associated with higher fALFF (intensity of regional spontaneous brain activity) and higher GM volumes in thalamus, striatum, hippocampus, and the mid-occipital region, with co-occurring fractional anisotropy changes in superior longitudinal fascicules, anterior thalamic radiation, and forceps major; 2) higher fALFF but lower GM volume in dorsolateral prefrontal cortex related to worse cognition in schizophrenia; and 3) distinct domains of MCCB might exhibit dissociable multimodal signatures, e.g., increased fALFF in inferior parietal lobule particularly correlated with decreased social cognition. Medication dose did not relate to these findings in schizophrenia. Conclusions Our results suggest linked functional and structural deficits in distributed cortico-striato-thalamic circuits may be closely related to MCCB-measured cognitive impairments in schizophrenia.
KW - Diffusion magnetic resonance imaging (dMRI)
KW - Functional magnetic resonance imaging (fMRI)
KW - Gray matter
KW - MATRICS Consensus Cognitive Battery (MCCB)
KW - Multimodal fusion
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84941321374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941321374&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2015.02.017
DO - 10.1016/j.biopsych.2015.02.017
M3 - Article
C2 - 25847180
AN - SCOPUS:84941321374
SN - 0006-3223
VL - 78
SP - 794
EP - 804
JO - Biological psychiatry
JF - Biological psychiatry
IS - 11
ER -